Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Google Inc (GOOG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Google IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Google Inc vs Neurocrine Biosciences Inc — how do they compare? Google Inc trades at $371.33 (market cap $4.52T), while Neurocrine Biosciences Inc trades at $171.47 (market cap $17.30B). The key difference: Google Inc is far larger — about 261.3× Neurocrine Biosciences Inc's market cap, and Google Inc pays a 0.24% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

GOOGNBIX
Market Cap
$4.52T$17.30B
Volume
1,511,127
Sector
TechnologyHealth
52-Week High
$399.06$180.55
52-Week Low
$183.77$123.10
Enterprise Value
$4.49T$16.39B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $370.43, up 3.67% on the day, with strong bullish momentum from recent earnings beats and a consensus analyst price target of $457.50. The stock shows robust fundamentals with 2025 revenue of $402.84B, net income margin of 37.92%, and consistent cash flow growth. Technical indicators are bullish, with the current price near resistance at $374, while sentiment is positive due to Warren Buffett's recent endorsement and AI-driven growth prospects.

Outlook remains favorable with earnings growth and AI expansion as key catalysts, though regulatory risks and market volatility pose challenges. The stock offers upside potential aligned with analyst targets, supported by high institutional ownership and strong profitability metrics.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $171.81, down slightly by 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, and robust profitability metrics like a 98.17% gross margin. Recent news highlights pipeline advancements and a Zacks upgrade to Strong Buy, reflecting positive sentiment.

Outlook remains positive with a consensus price target of $195.75, implying 14% upside. Key opportunities include sustained revenue growth and pipeline progress, while risks involve execution on recent acquisitions and competitive pressures. The stock is well-positioned for momentum but requires monitoring of Q2 2026 results due July 30.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX